BAM Logo

Biotherapy : Infliximab

[Biotherapie : Infliximab]

EPTIS factsheet 587044 | Last revision 2019-06-17 | URL: https://www.eptis.bam.de/pts587044 https://www.eptis.bam.de/pts587044

PT provider
PT provider CTCB CTCB
Based in France
Language(s) English /French
Product groups Health care / medical devices
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Quantification of Infliximab serum concentrations human serum all methods
• Anti-Infliximab antibodies detection and quantification human serum all methods
Aims of the PT scheme
Target group of participants merdical laboratories / no restriction to participation but possible extra charges according to the country
Linked to specific legislation / standards no
Additional, subsidiary aims
Number of participants 31
Accredited or otherwise reviewed by a 3rd party

Accredited by no on the basis of


Operation is commissioned / requested by no
Fees and frequency
Participation fee 428 euros
Regularly operated No
When will be the next round
Contact details of the PT provider
Provider Contact person
33 route de Bayonne

Phone: +33 (0)5 34 51 49 80
Fax: +33 (0)1 57 67 25 90
Web: https://www.ctcb.com/ https://www.ctcb.com/
Mrs Stéphanie Albarede
Phone: +33 (0)5 34 51 49 80
Fax: +33 (0)1 57 67 25 90
Email: s.albarede@ctcb.com s.albarede@ctcb.com
If you find any mistakes please contact the responsible EPTIS coordinator in France, Mr Patrick Bironneau. Mr Patrick Bironneau.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.21